Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass (CPB) in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting (CABG)
Sponsor: Orion Corporation, Orion Pharma
Listed as NCT00130871, this PHASE2 trial focuses on Coronary Heart Disease and remains completed. Sponsored by Orion Corporation, Orion Pharma, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jan 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Orion Corporation, Orion Pharma
For direct contact, visit the study record on ClinicalTrials.gov .